Robert Ives, GlaxoSmithKline - Qepler Summits And Conferences

Robert Ives

Investigator and Associate Fellow
GlaxoSmithKline
Stevenage, United Kingdom
The homepage of the GSK global corporate website

An in-vivo scientist with over 20 years of experience, Rob left full time education at 18 and decided to study part time for his bachelor’s Degree whilst working as an Associate Scientific Officer for a UK government medical research facility.

Here, Rob gained extensive knowledge working with new and old-world primates under category 2 and 3 containment conditions.

Since joining GlaxoSmithKline in 2001, Rob has taken lead roles in developing and refining technical procedures within the in-vivo world and has provided ad-hoc support and advice to the NC3Rs.

Rob led the inhaled delivery platform at Stevenage within Laboratory Animal Sciences before dedicating most of his time to developing and refining pre-clinical models of medicine palatability assessment.

He continues to lead collaborations with multiple external partners and has become an influential scientist within his field.

In 2017, Rob was accepted as an associate member of the GSK Society of Fellows, in recognition of his continuing contribution to advancing scientific understanding.

Related Sessions:

Inhaled Drug Delivery
Summit 2019

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 23 May 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 23 May 2019
BLOCK: FORMULATION, DEVELOPMENT & DESIGN.
CASE STUDY: ‘Bitter Matters’ – Assessing Inhaled Medicine Taste Preclinically.
  • Why taste matters: The patient experience
  • The importance of pre-clinical taste assessment to reduce late phase attrition
  • Modelling human taste preferences using rats: translatability
  • Limitations of inhaled formulations: the TRPM8 agonist, menthol as an excipient?
View Details